If your law firm is embarking on a Truvada marketing campaign, Atraxia Media can help.
Our team serves law firms nationwide, helping our clients resolve their challenges in acquiring new client business. Through our people-based and data-driven marketing strategies, we can help you qualify and retain more claims from individuals who suffered side effects from Truvada. Many patients who take Truvada, and similar HIV drugs that are part of the class of medications known as tenofovir disoproxil fumarate (TDF), are suing the drug producer Gilead Sciences, Inc. TDF drugs are also sold under the names Atripla, Complera, Stribild, Symfi-Lo, and Viread among other lesser-known brands.
Current signed contract costs: ***subject to change
At Atraxia Media, we help your law firm with effective and measurable marketing that achieves caseload goals. We've set in place an intake strategy that helps us assist your team in quickly onboarding clients who have been injured as a result of taking Truvada:
Patients may be eligible to get into Truvada litigation and get compensation for their injuries if they:
Atraxia Media is the first step toward better cases for your law firm. You need dependable marketing services as well as signed contracts that meet your requirements. For advertising and marketing, we rely on social media, AdWords, radio, and television. Then, according to your specifications, our in-house contract and intake professionals screen and vet potential Plaintiffs, ensuring that you receive a qualified contract. We only need to know the volume you require, and we'll provide you with superior marketing, contracts, and cases.
Truvada claims against Gilead Sciences, Inc. are still new, and, accordingly, settlements have not yet been reached. However, potential lawsuits of thousands of people who have suffered from the serious complications of Truvada are still expected. In addition, people who took Gilead's other HIV drugs containing TDF (Viread, Atripla, Complera, Stribild) have also filed lawsuits for compensation. The individual lawsuits were consolidated into multidistrict litigation (MDL) in December 2018, but the MDL was terminated in February 2019.
Gilead Sciences and other drugmakers also face a growing number of HIV drug class-action lawsuits. Each seeks class-action status to pursue damages against the pharmaceutical companies for all individuals or entities that purchased HIV drugs for use in a cART regimen, alleging that the companies engaged in a long-running scheme to control the market.
Truvada is a pill-based drug that prevents HIV cells from multiplying but does not cure HIV-1 infections or AIDS. Instead, the drug's role is to help reduce the risk of getting HIV-1 infections. Gilead's inaugural HIV drug, Viread, received U.S. Food and Drug Administration (FDA) approval in 2001. Gilead bought the rights to TDF - that had been around since the 1980s but was not feasible for AIDS treatment - and modified it to be taken orally in pill form. That is when the drug started getting used to stop HIV from taking hold and prevent it from spreading.
Several studies have linked Truvada and the other TDF-based HIV pills with serious side effects, including bone density loss, lactic acidosis, and kidney problems. These side effects have led to hundreds of Truvada lawsuits against Gilead Sciences, Inc.
TENOFOVIR DISOPROXIL FUMARATE PRODUCTS LIABILITY LITIGATION, NO. 2881 (TERMINATED)
Allegations against Gilead Sciences, Inc include:
Your legal team is undoubtedly experienced and well-equipped to deal with cases in mass tort litigation, but it's often difficult to address every potential client. This is especially true when news breaks and you receive a flood of calls seeking legal advice.
At Atraxia Media, because of our robust infrastructure, technology, and experience, we can ensure that your mass tort Truvada campaign will be as successful as possible. We can efficiently and effectively handle the advertising, screening, and qualifying of your firm's potential clients that mass tort litigation requires. Call us today if your firm is interested in increasing your client base and revenue for mass tort campaigns.